STOCKHOLM--(BUSINESS WIRE)--In her comments in today’s quarterly report, Elisabeth Lindner, President and CEO of Diamyd Medical (Pink Sheets:DMYDY) (STO:DIAMB), notes that a new chapter has begun in the Company’s history with last week’s agreement with Ortho-McNeil-Janssen Pharmaceuticals, Inc., to develop and commercialize the Diamyd® diabetes therapy.
